Susan Sweat, MD
Urology · Merriam, KSNPI 1447200084
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (45.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intuitive Surgical at 48.0% of the total. Reporting peaked in 2019 at $9,355 and has fallen 61.7% since, to $3,579 in 2025. Among urology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $106.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- Teleflex LLC$4K
- Procept Biorobotics Corporation$4K
- Astellas Pharma US Inc$314
- Johnson & Johnson$281
- Pfizer$247
- plus $2K from 25 others
What the payments were for
- Travel & lodging$9,29146%
- Food & beverage$6,94134%
- Education$4,03420%
- Gifts$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 39 | $9,743 |
| Teleflex LLC | 25 | $4,428 |
| Procept Biorobotics Corporation | 31 | $3,705 |
| Astellas Pharma US Inc | 8 | $314 |
| Johnson & Johnson | 13 | $281 |
| Pfizer | 13 | $247 |
| AbbVie(2 entities) | 14 | $195 |
| Olympus America Inc. | 8 | $146 |
| Boston Scientific | 3 | $132 |
| Sumitomo Pharma America, Inc. | 1 | $125 |
| Coloplast | 7 | $111 |
| SWAN Valley Medical Incorporated | 1 | $105 |
| Conmed Corporation | 1 | $83 |
| Photocure Inc | 1 | $70 |
| Rochester Medical Corporation | 2 | $67 |
| Convatec Inc. | 3 | $64 |
| Antares Pharma, Inc. | 1 | $64 |
| TELA Bio, Inc. | 1 | $56 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $52 |
| Immunitybio, Inc. | 1 | $49 |
| Axonics, Inc. | 3 | $47 |
| KARL Storz Endoscopy-america | 2 | $36 |
| Urovant Sciences Inc | 2 | $32 |
| Mission Pharmacal Company | 1 | $27 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Smith+Nephew | 1 | $19 |
| Calyxo, Inc. | 1 | $18 |
| Urogen Pharma, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Kerecis Limited | 1 | $14 |
| Osiris Therapeutics Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,025
- UroLift$3,121
- AquaBeam Robotic System$3,036
- Barrigel$1,344
- UroLift System$884
- GEMTESA$125
- AQUABEAM SYSTEM$117
How this compares
$20,295 in reported general payments places this provider in the 90th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 56 | $40,029 |
| MyrbetriqMirabegron | 44 | $39,026 |
| Methenamine Hippurate | 152 | $14,068 |
| XyostedTestosterone Enanthate | 16 | $9,784 |
| Tamsulosin Hcl | 399 | $4,809 |
| Trospium Chloride | 62 | $4,547 |
| Potassium Citrate ErPotassium Citrate | 34 | $2,985 |
| Silodosin | 36 | $2,776 |
| Estradiol | 40 | $2,546 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 65 | $1,916 |
| Solifenacin Succinate | 34 | $1,743 |
| Finasteride | 98 | $1,343 |
| Cephalexin | 196 | $1,328 |
| Dutasteride | 35 | $1,155 |
| Cefdinir | 59 | $1,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $125 | $40,02956 claims |
| Astellas Pharma US IncMyrbetriq | $314 | $39,02644 claims |
| Antares Pharma, Inc.Xyosted | $64 | $9,78416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 urology providers in Kansas.
Other urology in Merriam
- Son NguyenMerriam$27K
- Scott MontgomeryMerriam$11K
- John StricklandMerriam$7K
- Jeffrey MarksMerriam$6K
- William HerreMerriam$3K
- David EmmottMerriam$2K
- Timothy RichardsonWichita$493K
- Wilson MolinaKansas City$239K
- Bristol WhilesKansas City$163K
- Jeffrey HolzbeierleinKansas City$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.